Health · 1 sources covering this

STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit

On secondary endpoints that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·1h ago
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
On secondary endpoints that looked at major cardiovascular events, those taking retatrutide did not have a significant lower risk of death, heart attack, or stroke.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/659fdd1226d20aab3308653b681d8735f3341948"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit"></iframe>

STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit

How 1 sources are covering this

STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit

More from Health

This AI tool promises a 'second sight of eyes' to clinicians. Did patients benefit?

Expect a clash at today’s FDA peptide panel

Why health officials do not have a good handle on the current Ebola outbreak

Number of cyclosporiasis cases in the U.S. has surpassed previous records, CDC says

Reader

Trust & legal

Across the network